Weight reduction represents a significant secondary benefit of both medications
Mounjaro is not FDA approved for use as a weight loss drug
The share of covered workers enrolled in an HDHP/SO plan is larger in firms with 200 or more workers than the share in smaller firms (35% and 26%)
In studies using human fibroblast senescence models, the contents of the product were dissolved and added to the culture system at various concentrations
Cost-effectiveness outcomes were tested for a range of liraglutide price reductions, and these showed that oral semaglutide was considered dominant in every scenario with a 20% reduction applied to the liraglutide price, and dominant in all-but-one scenario with a 30% reduction applied to the liraglutide price (Fig
Incretin-based anti-obesity medications The development of next-generation anti-obesity medications (AOMs), such as incretin-based GLP-1 receptor agonists, offers promising potential to reduce the health impacts of obesity and improve overall public health outcomes, according to reports
